Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00204490 · ClinicalTrials.gov registry record · Phase 2
Soy Isoflavones and Breast Cancer Risk Reduction
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00204490 is a Phase 2 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 197 participants.
The verdict
NCT00204490, a Phase 2 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are currently unclear. Breast density has been considered as a breast cancer risk marker. We hypothesize that because isoflavones have estrogen-like activities, breast density and possibly bone density will be lower in women on soy-isoflavones.
Interventions
- DIETARY_SUPPLEMENT isoflavones
- DIETARY_SUPPLEMENT carbohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2004-04 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00204490
The ClinicalTrials.gov registry entry for NCT00204490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which isoflavones is the first listed.
NCT00204490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00204490 about?
NCT00204490 is a clinical study titled "Soy Isoflavones and Breast Cancer Risk Reduction". Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are currently unclear. Breast density has been considered as a breast cancer risk marker. We hypothesize ...
What is the current status of trial NCT00204490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2004-04. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT00204490?
The interventions under investigation include: isoflavones (DIETARY_SUPPLEMENT), carbohydrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00204490?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.